United Therapeutics (UTHR) Convertible Debt (2011 - 2013)

United Therapeutics (UTHR) has 3 years of Convertible Debt data on file, last reported at $207.4 million in Q1 2013.

• For the quarter ending Q1 2013, Convertible Debt rose 5.41% year-over-year to $207.4 million; the trailing twelve-month figure through Mar 2013 stood at $207.4 million (up 5.41% YoY), and the FY2012 full-year result was $204.7 million, up 5.4% from the prior year.
• Convertible Debt advanced to $207.4 million in Q1 2013, from $204.7 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $207.4 million in Q1 2013 to a low of $194.2 million in Q4 2011.
• A 3-year average of $200.7 million and a median of $200.7 million in 2012 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt climbed 5.4% in 2012 and climbed 5.41% in 2013, its largest moves.
• Tracing UTHR's Convertible Debt over 3 years: stood at $194.2 million in 2011, then advanced by 5.4% to $204.7 million in 2012, then gained by 1.33% to $207.4 million in 2013.
• Business Quant data shows UTHR's Convertible Debt at $207.4 million in Q1 2013, $204.7 million in Q4 2012, and $202.0 million in Q3 2012.